PMCID: PMC5103646 DOI: 10.5863/1551-6776-21.5.380
Increasingly, children and adolescents with dyslipidemia qualify for pharmacologic intervention. As they are for adults, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) are the mainstay of pediatric dyslipidemia treatment when lifestyle modifications have failed. Despite the overall success of these drugs, the magnitude of variability in dose-exposure-response profiles contributes to adverse events and treatment failure. In children, the cause of treatment failures remains unclear. This review describes the updated guidelines for screening and management of pediatric dyslipidemia and statin disposition pathway to assist the provider in recognizing scenarios where alterations in dosage may be warranted to meet patients' specific needs.
J Pediatr Pharmacol Ther
Lovastatin; Simvastatin; Atorvastatin; Fluvastatin; Pravastatin; Rosuvastatin Calcium; Dyslipidemias; Pharmacokinetics; Pharmacogenetics; Pediatrics
atorvastatin; dyslipidemia; fluvastatin; lovastatin; pediatrics; pharmacogenomics; pharmacokinetics; pravastatin; rosuvastatin; simvastatin; statin
Wagner J, Abdel-Rahman SM. Pediatric Statin Administration: Navigating a Frontier with Limited Data. J Pediatr Pharmacol Ther. 2016;21(5):380-403. doi:10.5863/1551-6776-21.5.380
Cardiology Commons, Cardiovascular Diseases Commons, Medical Genetics Commons, Medical Pharmacology Commons, Pediatrics Commons, Pharmaceutical Preparations Commons